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ABSTRACT The epidermal changes that occur in human
cutaneous immune responses have been investigated in the
tuberculin reaction and in the lesions of tuberculoid and
lepromatous leprosy and cutaneous leishmaniasis. In each
situation, there was a dermal accumulation of monocytes and
T cells, and the epidermis exhibited thickening. In the tuber-
culin response, the thickness of the epidermis sometimes
doubled in 48-72 hr, and this was attributed to increases in
both size and number of keratinocytes. In addition, the
phenotype of the keratinocytes changed from la- to Ia'.
Similar changes in keratinocyte Ia-antigen expression occurred
in the epidermis overlying untreated tuberculoid leprosy and
cutaneous leishmaniasis lesions, but not in lepromatous lepro-
sy. We suggest that one or more epidermal growth factors may
be generated in the course of a delayed immune reaction in the
dermis.
The cutaneous lesions of lepromatous leprosy are character-
ized by a sparse lymphocytic infiltrate and foamy macro-
phages laden with Mycobacteria leprae. In contrast, tuber-
culoid leprosy lesions exhibit large numbers of lymphocytes,
granuloma formation, and the absence of appreciable num-
bers of intracellular bacteria (1, 2). Monoclonal antibodies to
human leukocytes and their subsets have been used to
determine the phenotype of the cells in dermal infiltrates
(3-6). These studies showed that in lepromatous lesions there
is not only a marked reduction in the numbers of T cells
(compared to tuberculoid lesions) but also a selective absence
of T lymphocytes of the OKT4+ subset.
We wanted to establish whether this represented a specific
unresponsiveness to M. leprae antigens or a more general
defect in the emigration and accumulation ofOKT4+ T cells.
For this purpose we generated tuberculin reactions in the
dermis of lepromatous patients by use of the purified protein
derivative of tuberculin (PPD). During the course of these
studies, we observed striking changes in the thickness and
Ia-antigen expression of the epidermis overlying the PPD-
induced delayed-type hypersensitivity (DTH) lesions. Simi-
lar changes also occur in the epidermis overlying the lesions
of patients with tuberculoid leprosy and cutaneous leishma-
niasis.
MATERIALS AND METHODS
The Generation of DTH Response to PPD. After informed
consent was obtained, we evaluated the DTH response to 5
units of PPD in 90 Indian leprosy patients from New Delhi (a
highly endemic area for tuberculosis). The study group
included 25 lepromatous (LL) (see diagnosis below), 10
borderline lepromatous (BL), and 55 tuberculoid (BT and TT)
patients and 50 non-leprosy control individuals. Sex and age
distribution were as follows: BL and LL patients, 3 female
and 32 male, ages 16-68 (median 30) years; BT and TT
patients, 12 female and 43 male, ages 11-68 (median 30)
years; non-leprosy controls, 15 female and 35 male, ages
15-65 (median 28) years. The leprosy patients were examined
in collaboration with A. K. Sharma and R. S. Mishra (De-
partment of Dermatology, Safdarjung Hospital, New Delhi).
Antigen was injected intradermally into the leprosy lesions.
Two 4-mm punch-biopsy samples, one from the PPD-injected
leprosy lesion and one from an uninjected adjacent leprosy
lesion, were taken at 68-92 hr from consenting LL and BL
patients. The specimens were fixed as described below and
transported to the United States for further processing.
Additional Patient Populations. Leprosy. Skin biopsy sam-
ples (taken after informed consent was obtained) from 16
patients from Brazil, 6 patients from Colombia, and 4 patients
from the United States with various forms of leprosy were
examined. All patients were untreated at the time of biopsy.
The Brazilian patients were examined in collaboration with
the Department of Dermatology and General Pathology,
Hospital de Clinicas, Universidade do Rio de Janeiro. The
Colombian patients were studied in collaboration with the
Federico Lleras Acosta Hospital of Dermatology, Bogota.
The U.S. patients were studied in collaboration with W. R.
Levis (The Rockefeller University Hospital). Clinical diag-
nosis was accompanied by a histopathological diagnosis
established by us (I.N. and E.N.S.) and C. K. Job (Public
Health Service National Hansen's Disease Center, Carville,
LA) according to the Ridley-Jopling classification (7).
Cutaneous leishmaniasis. Patients with cutaneous leish-
maniasis were studied in collaboration with W. M. Rojas
(Corporacion para Investigiones Biologicas) and with M. I.
Restrepo and F. M. Restrepo (The Regional Health Labora-
tory, Medellin, Colombia). After informed consent was
obtained, 4-mm punch-biopsy specimens were taken from the
periphery of the lesions of 5 patients.
Fixation and Processing of Cutaneous Biopsy Samples. Skin
samples were fixed for 4 hr at 4°C in phosphate-buffered
saline (PBS) containing 3% (wt/vol) paraformaldehyde, 75
mM lysine, and 10 mM sodium metaperiodate, as described
by McLean and Nakane (8). This fixative preserves structural
details without inhibiting the binding of monoclonal antibod-
ies to their respective antigens (9). The biopsy samples were
stabilized for freezing by overnight washing in PBS contain-
ing 10% (wt/vol) sucrose and 40 ,uM digitonin, followed by
successive suspension in graded solutions of sucrose
Abbreviations: DTH, delayed-type hypersensitivity; PPD, purified
protein derivative of tuberculin.
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(15-25%). The samples were stored in PBS with 25% (wt/vol)
sucrose and 5% (vol/vol) glycerol until frozen.
Immunocytochemical Staining of Sections. The biopsy sam-
ples were embedded in OCT compound (Miles Scientific,
Naperville, IL) and frozen at -200C. Sections (6-8 ,m) were
cut on a cryostat and applied to gelatin-coated multiwell
slides (Carlson Scientific, Peotore, IL). The sections were
dried overnight at 370C, rehydrated in PBS, and incubated
with mouse monoclonal antibodies followed by biotinylated
horse anti-mouse Ig and then avidin-biotin-peroxidase com-
plexes (Vector Laboratories, Burlington, CA). The reaction
product was developed with diaminobenzidine (0.4 mg/ml) in
0.02 M Tris Cl buffer (pH 7.6) containing 0.03% H202.
Sections were counterstained with hematoxylin.
Monoclonal Antibodies. Mouse anti-human monoclonal
antibodies were used for the identification of specific cell
types. OKT6 (anti-thymocyte and Langerhans cells) was
obtained from Ortho Diagnostics (10); 9.3F10 (anti-HLA
class II) was produced in this laboratory (11); B8.11 (anti-
HLA-DR) and PSV-L3 (anti-HLA-DQ) were obtained from
R. deVries (Leiden, The Netherlands) (12, 13); VIC-Y1
(anti-human Ia invariant y chain) was obtained from W.
Knapp (Institute of Immunology, University of Vienna,
Austria) (14).
Evaluation of Staining and Morphological Changes. Adja-
cent sections were evaluated for specific cell staining with a
Zeiss light microscope. The thickness of the epidermis was
measured following projection of the section image onto a
television screen. At least 40 thickness determinations were
Table 1. PPD responsiveness in leprosy patients and in
non-leprosy control subjects
Diagnosis No. tested No. of responders (percent)
LL 25 14 (56)
BL 10 8 (80)
BT/TT 55 44 (80)
Non-leprosy 50 34 (68)
DTH reaction to a single injection of 5 units of PPD administered
intradermally to lepromatous leprosy (LL), borderline lepromatous
leprosy (BL), and borderline and tuberculoid leprosy (BT/TT)
patients and to non-leprosy control individuals was evaluated.
made at successive 100-gum intervals on each section, and the
mean and standard deviation of the mean were calculated.
This procedure resulted in the selection of sites that were
random with respect to the epidermal retia. In addition, the
number of keratinocyte cell layers was determined by count-
ing the number of cells between the basal and keratinized
layers in at least 30 random evenly spaced sites ofthe section.
RESULTS
PPD Responsiveness in Leprosy Patients. Leprosy patients
and non-leprosy control individuals were tested for their
responsiveness to an intradermal injection of 5 units of PPD
in 0.1 ml of diluent. Induration was measured 68-92 hr after
injection and considered positive if >10 mm. The respon-
Table 2. PPD responses and the changes in epidermal keratinocytes
Epidermal thickness Keratinocyte Ia
Patient Diagnosis Induration, mm Uninj., ,um PPD, ,um Ratio Uninj. PPD
1 LL 30 x 38 42 ± 9 86 ± 13 2.0 - +
2 LL 32 x 38 70 ± 13 76 ± 20 1.1 - +
3 LL 33 x 35 30 ± 8 80 ± 31 2.7 - +
4 BL 25 x 25 38 ± 10 49 ± 13 1.3 - +
5 LL 22 x 22 48 ± 16 94 ± 31 2.0 + +
6 LL 22 x 22 71 ± 27 107 ± 43 1.5 NT +
7 LL 20 x 22 29 ± 8 70 ± 25 2.4 - +
8 LL 20 x 20 48 ± 17 78 ± 23 1.6 - +
9 LL 20 x 20 39 ± 7 68 ± 19 1.7 - +
10 LL 19X 21 52 ± 15 99 ± 26 1.9 - +
11 LL 20 x 20 56 ± 25 86 ± 40 1.5 - +
12 LL 18 x 20 59 ± 15 94 ± 16 1.6 - +
13 BL 16 x 17 53 ± 18 101 ± 30 1.9 - +
14 BL 16 x 16 64 ± 20 105 ± 31 1.6 - +
15 LL 16 x 16 49 ± 15 118 ± 39 2.4 + +
16 BL/LL 15 x 17 45 ± 17 56 ± 19 1.2 - +
17 BL/LL 15 x 15 37 ± 16 85 ± 24 2.3 - +
18 LL 12 x 12 44 ± 21 87 ± 26 2.0 - +
19 LL(ENL)* 12 x 12 41 ± 11 70 ± 23 1.7 - +
20 BL 11x 12 42 ± 20 65 ± 27 1.5 - +
21 LL 8x 10 45 ± 21 82 ± 35 1.8 - +
22 LL 8x 12 47 ± 15 52 ± 18 1.1 - +
23 LL None 39 ± 17 56 ± 17 1.4 - +
24 BL 2 x 2 NT NT NT NT -
25 LL None 50 ± 20 63 ± 24 1.3 - -
26 LL None 41 ± 13 37 ± 10 0.9 + +
27 LL None 54 ± 16 44 ± 24 0.8 + +
28 BL None 69 ± 23 57 ± 18 0.8
Lepromatous (LL) and borderline lepromatous (BL) leprosy patients were tested for their response to a single injection
of 5 units of PPD. The induration was measured in mm. Epidermal thickness in uninjected leprosy lesions (Uninj.) and
PPD-injected lesions (PPD) was measured as described in Materials and Methods; results are expressed as mean thickness
± SD (in ,um). Ratio = thickness of the PPD lesion divided by the thickness of the uninjected lesion. Keratinocyte Ia was
evaluated and expressed as follows: +, all keratinocytes stained; ±, foci of stained keratinocytes; -, no keratinocyte
stained. NT, not tested.
*ENL, erythema nodosum leprosum.
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FIG. 1. Reaction of epidermal cells to a positive
PPD reaction. Photomicrographs are shown of
sections through the epidermis of uninjected lepro-
sy lesions (a and c) and PPD-responsive injected
lesions (b and d) of patients 3 (a and b) and 10 (c and
d). In b and d, thickening of the epidermis, accom-
panied by enhanced numbers and enlargement of
the keratinocytes, is observed. (Hematoxylin/eosin
stain; x250.)
siveness of this patient population is shown in Tables 1 and
2. The frequency of responders among patients with LL was
not significantly different from that among non-leprosy con-
trol subjects (56 and 68%, respectively). A higher percentage
(80%) of BT/TT patients were PPD-reactive. Responders
from all three patient groups (LL, BL, BT/TT) and from the
non-leprosy control group showed no differences in the
extent of induration.
All patients responding to PPD had dermal infiltrates
containing large numbers of monocytes, OKT4' and OKT8'
T cells (ratio about 2:1), and other cellular components,
similar histologically to the DTH response to PPD reported
in normal tuberculin responders (15-18). The composition of
these dermal infiltrates will be reported in more detail
elsewhere.
c
PPD Responsiveness and the Reaction of Epidermal
Keratinocytes. The delayed dermal response of the tuberculin
reaction was accompanied by marked changes in the epider-
mis. The epidermis overlying the indurated PPD site thick-
ened relative to the epidermis overlying the uninjected site(Fig. 1). Epidermal thickening was sometimes >2-fold in
responsive patients (Table 2). A limited correlation between
the extent of induration and epidermal thickening was ob-
served (correlation coefficient 0.526). The biopsy samples
taken from patients with negative PPD reactions (<10 mm)
failed to show epidermal thickening relative to uninjected
control sites. The change in epidermal thickening was asso-
ciated with increases in both the size and the number of
keratinocytes (Figs. 1 and 2). Quantitation indicated that the
epidermis of uninjected lesions contained an average of
FIG. 2. Expression of keratinocyte Ia in re-
sponse to intradermal tuberculin reactions. Photo-
micrographs of anti-Ia (9.3F10) monoclonal anti-
body staining of the epidermal cells of uninjected
leprosy lesions (a, c, and e) and tuberculin-respon-
sive injected lesions (b, d, and f) ofpatients 3 (a and
b), 7 (c and d), and 28 (e and f). Keratinocyte Ia
staining is observed only in the lesion from the PPD
response sites. The dark areas in the basal layer of
the uninjected sites are due to melanin. (a and b,
X100; c-f, x250.)
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FIG. 3. Expression of keratinocyte la in an untreated tuberculoid
leprosy lesion, shown by anti-Ia staining of the epidermal cells.
Epidermal thickening and Ia staining of the keratinocytes are
observed. (x250.)
3.5-5.9 (mean 4.6 ± 0.7) epidermal cell layers, whereas that
of PPD reactions was 5.1-8.5 (mean 7.1 ± 0.9) layers.
Keratinocytes in the epidermis of uninjected lesions were
flatter than those observed in PPD-positive lesions.
In addition to the thickening of the epidermis, the Ta
expression of the keratinocytes changed as a result of the
tuberculin reaction in the dermis. Most if not all the
keratinocytes of 20/22 patients became Ia' after the induc-
tion of the DTH reaction (Fig. 2). The keratinocytes were
HLA-DR+, HLA-DQ- and showed a weak cytoplasmic
staining for the invariant y chain (Inv). As a control, we noted
that both dermal macrophages and epidermal Langerhans
cells were DR+, DQ+, Inv+. In contrast, the keratinocytes of
5/6 non- or low responders remained 1a-. The keratinocyte
changes were unrelated to the number and size of OKT6+,
Ia+ Langerhans cells.
Expression of Keratinocyte la Antigen in Lesions of Untreat-
ed Leprosy Patients. The epidermal modifications associated
with the accumulation of T cells and monocytes in the
tuberculin reaction suggested that similar epidermal changes
might occur in the lesions of tuberculoid leprosy. Lesions of
untreated polar and borderline forms of the disease were
biopsied. A representative example of a tuberculoid lesion is
shown in Fig. 3. All of the tuberculoid patients and 5/6
borderline tuberculoid patients exhibited Ia+ keratinocytes
(Table 3), whereas none of the biopsies from polar lepro-
matous patients showed reactive cells. Again, epidermal Ia
expression could not be attributed to staining of OKT6+, Ia'
Langerhans cells. Thickening of the epidermis overlaying the
lesions was observed in many of the tuberculoid leprosy
lesions but could not be evaluated more accurately because
no control biopsy samples of normal skin were available for
these patients.
Cutaneous Lesions of Leishmaniasis. A large accumulation
of mononuclear cells occurs at the edge of the lesions of
cutaneous leishmaniasis. Examination of biopsy specimens
from five Colombian patients revealed extensive epidermal
thickening over the area of dermal infiltrate (Fig. 4). Each of
Table 3. Keratinocyte Ia in lesions of leprosy patients
Incidence of
No. of keratinocyte Ia'
Diagnosis* patients + ± -
LL 9 0 0 9
BL 6 1 0 5
BT 6 3 2 1
TT 4 2 2 0
All patients tested were untreated at the time of biopsy.
*See legend to Table 1 for abbreviations.
tScored as follows: +, all keratinocytes stained; ±, foci of stained
cells; -, no keratinocytes stained.
FIG. 4. Expression of keratinocyte Ia in a cutaneous leishman-
iasis lesion, shown by anti-Ia staining of the epidermal cells.
Extensive epidermal thickening and Ia staining of keratinocytes are
observed. (xlO0.)
the five patients showed strongly positive Ia staining outlin-
ing the enlarged spherical keratinocytes.
DISCUSSION
The common denominator in each ofthe epidermal responses
reported here is the accumulation of T lymphocytes and
monocytes in the dermis. These infiltrates, induced by the
local administration of antigen into sensitized hosts, repre-
sent the classic DTH response (15-18). In the case of the
intradermal tuberculin reaction, these cells were present for
no longer than 3 days. In tuberculoid leprosy and cutaneous
leishmaniasis, the lesions had existed for many months,
although the longevity of individual T cells and mononuclear
phagocytes in the infiltrates is unknown. In each case,
however, epidermal thickening and the expression of
keratinocyte Ia antigen on the cell surface had taken place.
Epidermal thickening is not a well-described feature ofDTH,
although it was noted by Turk (15) in the guinea pig tuberculin
reaction. Gut epithelial hyperplasia has been described in the
mucosal alterations during graft-vs.-host disease (19). En-
hanced expression of epidermal and epithelial Ia has also
been described in other cell-mediated immune responses (20,
21). Increased Ia expression could not be accounted for by an
increase in the numbers or size of Ia' Langerhans cells.
Using the OKT6 monoclonal antibody to identify Langerhans
cells, we found that the numbers of OKT6+ cells in the
epidermis was often reduced during a DTH response. These
results will be reported in more detail elsewhere.
In a clinical trial we are now conducting at the Hospital of
The Rockefeller University, recombinant interferon 'y
(Genentech, South San Francisco) has been administered
intradermally (Medajet gun) into the lesions of patients with
lepromatous leprosy. Our findings, which will be published
elsewhere, include a rapid (6-day) increase in epidermal
thickness and the marked expression of la antigen on the
surface of the keratinocytes. Therefore, interferon y may,
either directly or through secondary reactants, be a signifi-
cant stimulator for the keratinocyte changes in DTH. The
situation may be more complex if keratinocyte growth and Ia
expression are generated by separate stimuli. Ia expression
can be induced in a number of cell types by interferon y, and
in macrophages this is unrelated to cell division (22-25).
Assuming interferon y is involved in inducing the epidermal
changes, our observations suggest that the infiltrating T cells
ofthe dermal lesions oftuberculoid leprosy release interferon
y locally, leading to keratinocyte Ia expression and epidermal
thickening, whereas the infiltrating cells of the lepromatous
lesions do not release interferon y. This model is consistent
with our in vitro observations that peripheral blood lympho-
cytes from patients with tuberculoid leprosy release interfer-
on y in response to M. leprae, whereas cells from lepro-
matous leprosy patients release little or none (33).
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The thickening of the epidermis, when coupled with
changes in keratinocyte shape, larger numbers of cell layers,
and greater numbers of mitotic figures, suggests that
keratinocytes are undergoing more rapid growth, although
modified keratinocyte differentiation must also be consid-
ered. We favor the idea that one or more epidermal growth
stimulants are generated by the dermal cell populations or by
the epidermis in response to cell-mediated immunity. Two
agents that induce keratinocyte replication have been noted.
(i) Stimulation of adenylate cyclase activity by cholera toxin
promotes replication (reviewed in ref. 26). (ii) Epidermal
growth factor(s) from a variety of cell types may be respon-
sible for promoting replication (27). Establishing whether
these mechanisms are operative in delayed-type reactions
will require the use of keratinocyte cultures. The complex
milieu of the DTH reaction contains many cell types and
secreted cellular products that may be the source of the
epidermal stimulant. These include T cells and their secreted
lymphokines (28, 29), macrophages and their extensive
secretory repertoire (30), fibroblasts (31), and even kerati-
nocytes (32) themselves.
Additional questions remain concerning the rate of appear-
ance and persistence of the epidermal changes, the role of
other inflammatory cells, and the responsiveness of the skin
of the normal control subjects. The generation of a number of
soluble factors during an immune response, including inter-
leukin 2, interferon y, and epidermal growth factor(s), may
promote the healing and closure of wounds.
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